Literature DB >> 26410555

Therapeutic effects of an anti-ADAMTS-5 antibody on joint damage and mechanical allodynia in a murine model of osteoarthritis.

R E Miller1, P B Tran2, S Ishihara2, J Larkin3, A M Malfait4.   

Abstract

OBJECTIVE: The primary goal of this study was to test the disease-modifying effect of blocking a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)-5 with a neutralizing monoclonal antibody (mAb) starting 4 weeks after destabilization of the medial meniscus (DMM) in the mouse. We also investigated whether ADAMTS-5 blockade reversed mechanical allodynia and decreased monocyte chemoattractant protein (MCP)-1 production by dorsal root ganglia (DRG) cells.
METHODS: Ten-week old male C57BL/6 mice underwent DMM surgery and were either left untreated or treated with anti-ADAMTS-5 mAb or IgG2c isotype control mAb starting 4 weeks after surgery. Knees were collected for histopathology 4 or 12 weeks later. Mechanical allodynia was monitored biweekly in the ipsilateral hind paw through 16 weeks. DRG were collected and cultured 8 weeks after DMM for analysis of MCP-1 production.
RESULTS: By 4 weeks after DMM, mild cartilage degeneration was evident in the medial compartment, small osteophytes were present, and subchondral bone sclerosis was established. By 16 weeks after surgery, significant cartilage deterioration was apparent on the medial tibial plateaux and medial femoral condyles, osteophyte size had increased, and subchondral bone sclerosis was maintained. Treatment with ADAMTS-5 mAb from week 4 to 16 after surgery slowed cartilage degeneration and osteophyte growth but did not affect subchondral bone sclerosis. Moreover, ADAMTS-5 blockade resulted in temporary reversal of mechanical allodynia, which correlated with decreased MCP-1 production by cultured DRG cells.
CONCLUSIONS: This study suggests therapeutic efficacy of an ADAMTS-5 mAb in the DMM model, when therapy starts early in disease.
Copyright © 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ADAMTS-5; Mouse model; Osteoarthritis; Pain

Mesh:

Substances:

Year:  2015        PMID: 26410555      PMCID: PMC4743933          DOI: 10.1016/j.joca.2015.09.005

Source DB:  PubMed          Journal:  Osteoarthritis Cartilage        ISSN: 1063-4584            Impact factor:   6.576


  31 in total

1.  Targeting of ADAMTS5's ancillary domain with the recombinant mAb CRB0017 ameliorates disease progression in a spontaneous murine model of osteoarthritis.

Authors:  R Chiusaroli; M Visentini; C Galimberti; C Casseler; L Mennuni; S Covaceuszach; M Lanza; G Ugolini; G Caselli; L C Rovati; M Visintin
Journal:  Osteoarthritis Cartilage       Date:  2013-08-15       Impact factor: 6.576

Review 2.  Identifying and treating preclinical and early osteoarthritis.

Authors:  David T Felson; Richard Hodgson
Journal:  Rheum Dis Clin North Am       Date:  2014-09-12       Impact factor: 2.670

3.  Identification of potent and selective hydantoin inhibitors of aggrecanase-1 and aggrecanase-2 that are efficacious in both chemical and surgical models of osteoarthritis.

Authors:  Timothy B Durham; Valentine J Klimkowski; Christopher J Rito; Jothirajah Marimuthu; James L Toth; Chin Liu; Jim D Durbin; Stephanie L Stout; Lisa Adams; Craig Swearingen; Chaohua Lin; Mark G Chambers; Kannan Thirunavukkarasu; Michael R Wiley
Journal:  J Med Chem       Date:  2014-12-05       Impact factor: 7.446

4.  The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse.

Authors:  S S Glasson; T J Blanchet; E A Morris
Journal:  Osteoarthritis Cartilage       Date:  2007-04-30       Impact factor: 6.576

5.  Depletion of protease-activated receptor 2 but not protease-activated receptor 1 may confer protection against osteoarthritis in mice through extracartilaginous mechanisms.

Authors:  Miriam T Jackson; Babak Moradi; Sanaa Zaki; Margaret M Smith; Sharon McCracken; Susan M Smith; Christopher J Jackson; Christopher B Little
Journal:  Arthritis Rheumatol       Date:  2014-12       Impact factor: 10.995

6.  CCR2 chemokine receptor signaling mediates pain in experimental osteoarthritis.

Authors:  Rachel E Miller; Phuong B Tran; Rosalina Das; Nayereh Ghoreishi-Haack; Dongjun Ren; Richard J Miller; Anne-Marie Malfait
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-26       Impact factor: 11.205

7.  Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and disease development.

Authors:  Andrew D Cook; Jarrad Pobjoy; Stefan Steidl; Manuela Dürr; Emma L Braine; Amanda L Turner; Derek C Lacey; John A Hamilton
Journal:  Arthritis Res Ther       Date:  2012-09-20       Impact factor: 5.156

8.  Differential transcriptional profiling of damaged and intact adjacent dorsal root ganglia neurons in neuropathic pain.

Authors:  A K Reinhold; L Batti; D Bilbao; A Buness; H L Rittner; P A Heppenstall
Journal:  PLoS One       Date:  2015-04-16       Impact factor: 3.240

9.  Disease progression and phasic changes in gene expression in a mouse model of osteoarthritis.

Authors:  Richard F Loeser; Amy L Olex; Margaret A McNulty; Cathy S Carlson; Michael Callahan; Cristin Ferguson; Jacquelyn S Fetrow
Journal:  PLoS One       Date:  2013-01-28       Impact factor: 3.240

10.  Osteoprotegerin reduces the development of pain behaviour and joint pathology in a model of osteoarthritis.

Authors:  Devi Rani Sagar; Sadaf Ashraf; Luting Xu; James J Burston; Matthew R Menhinick; Caroline L Poulter; Andrew J Bennett; David A Walsh; Victoria Chapman
Journal:  Ann Rheum Dis       Date:  2013-05-30       Impact factor: 19.103

View more
  32 in total

1.  Microarray analyses of the dorsal root ganglia support a role for innate neuro-immune pathways in persistent pain in experimental osteoarthritis.

Authors:  R E Miller; P B Tran; S Ishihara; D Syx; D Ren; R J Miller; A M Valdes; A M Malfait
Journal:  Osteoarthritis Cartilage       Date:  2020-01-23       Impact factor: 6.576

2.  The nociceptive innervation of the normal and osteoarthritic mouse knee.

Authors:  A M Obeidat; R E Miller; R J Miller; A-M Malfait
Journal:  Osteoarthritis Cartilage       Date:  2019-07-25       Impact factor: 6.576

3.  Spinal microglial activation in a murine surgical model of knee osteoarthritis.

Authors:  P B Tran; R E Miller; S Ishihara; R J Miller; A M Malfait
Journal:  Osteoarthritis Cartilage       Date:  2016-09-16       Impact factor: 6.576

4.  An aggrecan fragment drives osteoarthritis pain through Toll-like receptor 2.

Authors:  Rachel E Miller; Shingo Ishihara; Phuong B Tran; Suzanne B Golub; Karena Last; Richard J Miller; Amanda J Fosang; Anne-Marie Malfait
Journal:  JCI Insight       Date:  2018-03-22

5.  Chemogenetic Inhibition of Pain Neurons in a Mouse Model of Osteoarthritis.

Authors:  Rachel E Miller; Shingo Ishihara; Bula Bhattacharyya; Ada Delaney; Daniela M Menichella; Richard J Miller; Anne-Marie Malfait
Journal:  Arthritis Rheumatol       Date:  2017-06-02       Impact factor: 10.995

6.  Nanoindentation modulus of murine cartilage: a sensitive indicator of the initiation and progression of post-traumatic osteoarthritis.

Authors:  B Doyran; W Tong; Q Li; H Jia; X Zhang; C Chen; M Enomoto-Iwamoto; X L Lu; L Qin; L Han
Journal:  Osteoarthritis Cartilage       Date:  2016-08-25       Impact factor: 6.576

7.  Visualization of Peripheral Neuron Sensitization in a Surgical Mouse Model of Osteoarthritis by In Vivo Calcium Imaging.

Authors:  Rachel E Miller; Yu Shin Kim; Phuong B Tran; Shingo Ishihara; Xinzhong Dong; Richard J Miller; Anne-Marie Malfait
Journal:  Arthritis Rheumatol       Date:  2017-12-01       Impact factor: 10.995

8.  Chemokine receptor-7 (CCR7) deficiency leads to delayed development of joint damage and functional deficits in a murine model of osteoarthritis.

Authors:  Nisha Sambamurthy; Vu Nguyen; Ryan Smalley; Rui Xiao; Kurt Hankenson; Justin Gan; Rachel E Miller; Anne-Marie Malfait; George R Dodge; Carla R Scanzello
Journal:  J Orthop Res       Date:  2017-08-29       Impact factor: 3.494

Review 9.  ADAMTS-5: A difficult teenager turning 20.

Authors:  Salvatore Santamaria
Journal:  Int J Exp Pathol       Date:  2020-03-27       Impact factor: 1.925

Review 10.  Monoclonal antibodies against metzincin targets.

Authors:  Salvatore Santamaria; Rens de Groot
Journal:  Br J Pharmacol       Date:  2018-04-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.